Equity
€41,535 ▲ 32.6%
VIPHARMA has made a profit without a break since 2023.
VIPHARMA
Lifetime
4 annual accounts with figures on one time axispeak €96,752 (2023)
€86,908▼ 7.6%
lowest -€19,520 (2022)
€10,208▼ 54.7%
peak €41,535 (2025)
€41,535▲ 32.6%
€425,560▼ 3.2%
peak 1.1 FTE (2022)
0.8 FTEunchanged
Board1 name since 2021
1 director
Documentsfilings and deeds
31-03-2026122 days before the deadline
2025financial year
Result from €22,534 to €10,208Equity from €31,327 to €41,535
Key points
from the 2025 annual accountsTurnover
≈ €420,000 estimated
The accounts state no turnover.
Debts
€425,560 91% of the balance sheet
Financial debts 26%Suppliers 10%Taxes and wages 2%Other 62%
Of this, €315,784 falls due within a year.
Filings
4 annual accounts since 2022
The last four annual accounts were filed 44 to 122 days before the end of the period.
Starting capital
€100
Position in the sector
€41,535
Less equity than 84% of companies in retail trade. Sector median €557,228 · 2,453 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 1,250 companies had the same profile as VIPHARMA has now. Each dot stands for 4 companies, two years later.
94.4%
were still trading
2.7%
stopped another way
2.6%
went bankrupt
Another 0.3% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 1,250 companies, not a prediction for VIPHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0774494916
First establishment
Rue Désiré Blondiau 90, Saint-Ghislain
Incorporation
Founding capital of €100 · Founder: · Appointment: (director) · published on 27-09-2021 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| VIPHARMA Saint-Ghislain | €467,095 | €86,908 | 8.9% | 0.8 |
| HUMAN PHARMA Charleroi | €434,132 | €114,557 | 51.8% | 0.8 |
| Pharmacie Nathalie Elsen Andenne | €468,661 | €113,594 | 10.5% | 0.5 |
| PHARMACIE DU LAC Rixensart | €399,426 | €103,305 | 30.5% | 0.9 |
| MONOPHAR Beernem | €411,797 | €138,416 | 11.4% | 1 |
| PHARMACIE BESONRIEUX CENTRE La Louvière | €377,209 | €81,334 | 2.1% | 1.2 |
| PHARMACIE SIRAUT Mons | €327,341 | €119,483 | 1.0% | 1 |
These companies have the same main activity as VIPHARMA: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €327,000 and €469,000, founded between 2019 and 2023.
Official details
Source: KBO- Status
- Active since 23-09-2021Normal situation
- Activity
- Retail sale of pharmaceutical productsNACE 47730
- Joint committee
- 313Pharmacies and pricing offices · annual accounts 2025
- Establishment unit
- 2.324.727.9327332 Saint-Ghislain, since 31-12-2021
- Financial year end
- 31 December
- Peppol
- Reachable since 25-11-2025
Annual accounts 2025
- €467,095▼ 0.8%
- Employeeson 31-12-2025
- 1=
- Filing
- Filed on 31-03-2026, 122 days before the end of the filing period
Insights on VIPHARMA
VIPHARMA has been active since 2021 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €41,535 and a net result of €10,208.
Equity has been growing by about 84% per year since 2022. Its solvency ranks better than 21% of 2,453 sector peers (NACE 47, financial year 2025).
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about VIPHARMA
- What is the company number of VIPHARMA?
- The company number of VIPHARMA is 0774.494.916. The VAT number is the same number with BE in front: BE 0774.494.916.
- Where is VIPHARMA based?
- The registered office is at Rue Désiré Blondiau 90, 7332 Saint-Ghislain.Company details
- What does VIPHARMA do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of VIPHARMA?
- VIPHARMA is a private limited company (BV).
- When was VIPHARMA founded?
- VIPHARMA was founded on 23-09-2021.
- Is VIPHARMA still active?
- Yes, VIPHARMA is an active enterprise in the KBO register.
- How many employees does VIPHARMA have?
- VIPHARMA had an average of 0.8 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does VIPHARMA fall under?
- In its 2025 annual accounts, VIPHARMA states joint committee 313 (Pharmacies and pricing offices).
- What is the turnover of VIPHARMA?
- The turnover in financial year 2025 is ≈ €420,000. This figure is estimated from the gross margin of €86,908 and 74 comparable companies (NACE 477). It probably lies between €210,000 and €610,000.
- Is VIPHARMA profitable?
- In financial year 2025, VIPHARMA made a profit of €10,208.
- Where can I find the annual accounts of VIPHARMA?
- VIPHARMA filed 4 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of VIPHARMA due?
- VIPHARMA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.